Targapremir-210

• CAT Number: I020175
• CAS Number: 1049722-30-6
• Molecular Formula: C₃₂H₃₆N₁₀O₂
• Molecular Weight: 592.69
• Purity: ≥95%
• Target: Apoptosis
• Storage: Store at -20°C
• IUPAC Name: N-(3-azidopropyl)-4-[3-[6-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-benzimidazol-2-yl]phenoxy]butanamide
• InChI: InChI=1S/C32H36N10O2/c1-41-14-16-42(17-15-41)24-9-11-27-29(21-24)39-32(37-27)23-8-10-26-28(20-23)38-31(36-26)22-5-2-6-25(19-22)44-18-3-7-30(43)34-12-4-13-35-40-33/h2,5-6,8-11,19-21H,3-4,7,12-18H2,1H3,(H,34,43)(H,36,38)(H,37,39)
• InChIKey: PAYVJEWMAWLKAP-UHFFFAOYSA-N
• SMILES: CN1CCN(CC1)C2=CC3=C(C=C2)N=C(N3)C4=CC5=C(C=C4)N=C(N5)C6=CC(=CC=C6)OCCCC(=O)NCCCN=[N+]=[N-]

Targapremir-210（Cat No.:I020175）is a synthetic oligonucleotide designed to target and inhibit the activity of miR-210, a microRNA often associated with hypoxic conditions and tumor progression. By suppressing miR-210, Targapremir-210 aims to restore the expression of downstream genes involved in cell cycle regulation, apoptosis, and angiogenesis. This compound has shown potential in preclinical studies for its ability to inhibit tumor growth and enhance sensitivity to chemotherapy in various cancer models. Targapremir-210’s unique mechanism of action positions it as a promising therapeutic candidate for targeting miRNA-related pathways in cancer treatment.

Reference

[1]. Costales MG, et al. Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit. J Am Chem Soc. 2017 Mar 8; 139(9):3446-3455.